342 related articles for article (PubMed ID: 28825595)
1. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
Yuan H; Li N; Fu D; Ren J; Hui J; Peng J; Liu Y; Qiu T; Jiang M; Pan Q; Han Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Sep; 127(9):3375-3391. PubMed ID: 28825595
[TBL] [Abstract][Full Text] [Related]
2. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.
Zhang YL; Sun JW; Xie YY; Zhou Y; Liu P; Song JC; Xu CH; Wang L; Liu D; Xu AN; Chen Z; Chen SJ; Sun XJ; Huang QH
Cell Res; 2018 Apr; 28(4):476-490. PubMed ID: 29531312
[TBL] [Abstract][Full Text] [Related]
3. The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis.
Liu M; Rao H; Liu J; Li X; Feng W; Gui L; Tang H; Xu J; Gao WQ; Li L
Redox Biol; 2021 Jul; 43():102004. PubMed ID: 34020310
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling.
Jiang C; He C; Wu Z; Li F; Xiao J
Biochem Biophys Res Commun; 2018 Jul; 502(3):382-388. PubMed ID: 29842882
[TBL] [Abstract][Full Text] [Related]
5. The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness.
Grinat J; Heuberger J; Vidal RO; Goveas N; Kosel F; Berenguer-Llergo A; Kranz A; Wulf-Goldenberg A; Behrens D; Melcher B; Sauer S; Vieth M; Batlle E; Stewart AF; Birchmeier W
Nat Commun; 2020 Dec; 11(1):6422. PubMed ID: 33349639
[TBL] [Abstract][Full Text] [Related]
6. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
7. Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.
Feng W; Ma C; Rao H; Zhang W; Liu C; Xu Y; Aji R; Wang Z; Xu J; Gao WQ; Li L
Cancer Lett; 2023 Nov; 579():216470. PubMed ID: 37914019
[TBL] [Abstract][Full Text] [Related]
8. SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis.
Xie Y; Sahin M; Wakamatsu T; Inoue-Yamauchi A; Zhao W; Han S; Nargund AM; Yang S; Lyu Y; Hsieh JJ; Leslie CS; Cheng EH
JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810256
[TBL] [Abstract][Full Text] [Related]
9. SETD2-mediated epigenetic regulation of noncanonical Wnt5A during osteoclastogenesis.
Deb M; Laha D; Maity J; Das H
Clin Epigenetics; 2021 Oct; 13(1):192. PubMed ID: 34663428
[TBL] [Abstract][Full Text] [Related]
10. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.
Niu N; Lu P; Yang Y; He R; Zhang L; Shi J; Wu J; Yang M; Zhang ZG; Wang LW; Gao WQ; Habtezion A; Xiao GG; Sun Y; Li L; Xue J
Gut; 2020 Apr; 69(4):715-726. PubMed ID: 31300513
[TBL] [Abstract][Full Text] [Related]
11. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
12. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
Kumari S; Muthusamy S
Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
[TBL] [Abstract][Full Text] [Related]
13. Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway.
Ma C; Liu M; Feng W; Rao H; Zhang W; Liu C; Xu Y; Wang Z; Teng Y; Yang X; Ni L; Xu J; Gao WQ; Lu B; Li L
Clin Transl Med; 2023 Nov; 13(11):e1475. PubMed ID: 37962020
[TBL] [Abstract][Full Text] [Related]
14. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
15. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.
Yuan H; Han Y; Wang X; Li N; Liu Q; Yin Y; Wang H; Pan L; Li L; Song K; Qiu T; Pan Q; Chen Q; Zhang G; Zang Y; Tan M; Zhang J; Li Q; Wang X; Jiang J; Qin J
Cancer Cell; 2020 Sep; 38(3):350-365.e7. PubMed ID: 32619406
[TBL] [Abstract][Full Text] [Related]
16. SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing.
Zhu K; Lei PJ; Ju LG; Wang X; Huang K; Yang B; Shao C; Zhu Y; Wei G; Fu XD; Li L; Wu M
Nucleic Acids Res; 2017 Jan; 45(1):92-105. PubMed ID: 27614073
[TBL] [Abstract][Full Text] [Related]
17. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
[TBL] [Abstract][Full Text] [Related]
18. H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm.
Zhang Y; Xie S; Zhou Y; Xie Y; Liu P; Sun M; Xiao H; Jin Y; Sun X; Chen Z; Huang Q; Chen S
Cell Rep; 2014 Sep; 8(6):1989-2002. PubMed ID: 25242323
[TBL] [Abstract][Full Text] [Related]
19. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B
Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925
[TBL] [Abstract][Full Text] [Related]
20. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36.
de Almeida SF; Grosso AR; Koch F; Fenouil R; Carvalho S; Andrade J; Levezinho H; Gut M; Eick D; Gut I; Andrau JC; Ferrier P; Carmo-Fonseca M
Nat Struct Mol Biol; 2011 Jul; 18(9):977-83. PubMed ID: 21792193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
